The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India.
J Autoimmun. 2021 Sep;123:102688. doi: 10.1016/j.jaut.2021.102688. Epub 2021 Jul 3.
Unprecedented loss of life due to the COVID pandemic has necessitated the development of several vaccines in record time. Most of these vaccines have received approval without being extensively whetted for their adverse effect and efficacy profiles. Most adverse effects have been mild, nonetheless, more serious thromboembolic events have also been reported. Autoimmune hepatitis (AIH) can occur in predisposed individuals where an immune mediated reaction against hepatocytes is triggered by environmental factors. Vaccines are a very rare cause of AIH. We report two such cases of AIH triggered by COVID (Covishield) vaccination. While one patient made an uneventful recovery, another succumbed to the liver disease. Ours is the first report of Covishield vaccination related AIH and second ever after any form of COVID vaccination. We hope that our report does not deter COVID vaccination drives. However, we also hope to raise awareness of its potential side effects and the increased role of pharmacovigilance in guiding treatment.
由于 COVID 大流行,导致前所未有的生命损失,因此需要在创纪录的时间内开发出几种疫苗。这些疫苗中的大多数都未经广泛测试其不良反应和疗效就获得了批准。大多数不良反应都很轻微,但也有报道称更严重的血栓栓塞事件。自身免疫性肝炎(AIH)可发生在易患个体中,这些个体的肝细胞受到环境因素的影响而发生免疫介导的反应。疫苗是 AIH 的一个非常罕见的原因。我们报告了两例由 COVID(Covishield)疫苗接种引发的 AIH 病例。虽然一名患者康复顺利,但另一名患者则死于肝病。这是 Covishield 疫苗接种相关 AIH 的首例报告,也是继任何形式的 COVID 疫苗接种后的第二例报告。我们希望我们的报告不会阻止 COVID 疫苗接种工作。然而,我们也希望提高人们对其潜在副作用的认识,并增强药物警戒在指导治疗方面的作用。